Half-year report 2024

Half-year report 2024

High-precision delivery

medmix designs, develops, manufactures and delivers innovative high-precision devices and services for the mixing, application and injection of liquids in a wide range of viscosities for the healthcare, consumer and industrial end-markets. medmix shares are listed and traded on the SIX Swiss Exchange in Zurich (Securities No. 112.967.710/ISIN CH1129677105). 
Read more about medmix here

Letter to the shareholders

graphic graphic

Our KEY Figures

241.2 m CHF

revenue in H1 2024

19.1 %

adjusted EBITDA margin

7.6 m CHF

free cash flow generated in H1 2024

Financial Review Section

Financial and business review

graphic graphic

Financial reporting

graphic graphic